Intercept Pharmaceuticals Cash Flow Statement

Financials in millions VND. Fiscal year is January - December.

Millions VND. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Jan '24 Jan 1, 2024
Net Income	120,821	107,616	58,439
Depreciation & Amortization	48,436	40,593	58,381
Loss (Gain) From Sale of Assets	-36,981	-36,981	-58,311
Other Operating Activities	39,190	37,986	38,568
Change in Accounts Receivable	-5,146	325,957	-378,088
Change in Inventory	-12,471	190,031	-31,104
Change in Other Net Operating Assets	-76,572	-75,938	43,613
Operating Cash Flow	98,081	589,264	-268,431
Capital Expenditures	-1,334	-30.75	-13,236
Sale of Property, Plant & Equipment	-	207.27	-
Investment in Securities	-96,259	-96,259	-640.86
Other Investing Activities	42,010	45,499	36,674
Investing Cash Flow	-48,924	-104,053	96,632
Long-Term Debt Issued	-	1,445,113	1,849,807
Long-Term Debt Repaid	-	-1,904,143	-1,636,260
Net Debt Issued (Repaid)	-34,183	-459,031	213,547
Common Dividends Paid	-19,942	-27,275	-32,426
Financing Cash Flow	-54,125	-486,306	181,121
Net Cash Flow	-4,969	-1,094	9,322
Free Cash Flow	96,747	589,234	-281,667
Free Cash Flow Margin	29.47%	100.93%	-44.91%
Free Cash Flow Per Share	9674.18	58923.36	-28166.70
Cash Interest Paid	71,022	96,452	86,287
Cash Income Tax Paid	2,871	4,203	5,940
Levered Free Cash Flow	-	584,110	-
Unlevered Free Cash Flow	-	626,652	-
Change in Net Working Capital	-	-490,418	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.